Poly Medicure Intrinsic Value

POLYMED · NSE

— · —

Current market price

₹1,638.1

Closing price — 1 Oct 2026

Market cap ₹16,848 Cr · EPS ₹10.86

Valuation

Blended fair value using DCF and peer comparison methods.

Poly Medicure Intrinsic Value Analysis

The latest available EOD closing price for Poly Medicure (POLYMED) is ₹1,638 per share. Understock's estimated intrinsic value is ₹1,632 per share. This estimate is 0.3% below that price; the page's comparison band labels the shares fairly valued.

The stored DCF estimate is ₹702, and the peer-based estimate is ₹2,133. The displayed value combines them using the stored DCF weight of 35% and peer weight of 65%. Peer comparison uses 8 matched sector companies and contributing P/E, P/B, EV/EBITDA multiples.

For context, available company data reports ROCE of 9.6% and P/E of 52.4×. These metrics describe the business and are not separate intrinsic-value estimates.

How Understock Calculates Intrinsic Value

Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For Poly Medicure, the displayed estimate uses both stored values and their respective weights. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.

Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Poly Medicure peer valuation · What intrinsic value means

Company in heavy investment phase. DCF based on operating cash flow. Peer comparison weighted more heavily.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Poly Medicure Peer Comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Poly Medicure POLYMED · you	₹16,848 Cr	52.4×	5.4×	38.8×	10.4%	17.2%	18.9%
Sector median	—	77.4×	8.9×	36.1×	16.9%	9.3%	16.8%
Aster DM Healthcare ASTERDM	₹40,777 Cr	105.1×	8.9×	47.6×	8.5%	8.4%	15.7%
Narayana Hrudayalaya NH	₹39,489 Cr	47.9×	8.6×	28.2×	17.8%	10.2%	20.4%
Krishna Institute of Medical Sciences KIMS	₹33,983 Cr	126.6×	17.0×	—	13.4%	0.1%	—
Global Health MEDANTA	₹33,396 Cr	60.1×	8.4×	37.0×	14.0%	12.6%	17.9%
Rubicon Research Limited RUBICON	₹26,782 Cr	113.6×	—	—	—	0.2%	—
Dr. Lal Path Labs LALPATHLAB	₹26,409 Cr	52.2×	10.5×	35.1×	20.1%	18.3%	11.1%
AstraZeneca Pharma India Limited ASTRAZEN	₹17,766 Cr	94.7×	20.4×	67.4×	21.5%	8.2%	31.4%
Alivus Life Sciences Limited ALIVUS	₹16,540 Cr	29.9×	5.1×	20.4×	16.9%	22.1%	5.7%

Peer comparison verdict

Poly trades at a discount to sector peers on P/E (52.4× vs median 77.4×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

Business quality

Valuation

P/E ratio

52.4×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

10.4%

ROCE

9.6%

ROA

—

Growth

Revenue CAGR (3yr)

18.9%

EPS CAGR (3yr)

21.6%

Efficiency

Asset turnover

—

FCF yield

-0.4%

Dividend yield

0.2%

Liquidity & Solvency

Debt / Equity

0.02×

Debt / EBITDA

—

Interest coverage

25.4×

Current ratio

3.37×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Is the business financially healthy?

Two structured frameworks that go beyond a single number to assess financial strength.

Altman Z-Score

Predicts likelihood of financial distress. Above 2.99 = safe zone; 1.81–2.99 = grey zone; below 1.81 = distress.

12.08

Safe zone

0 (distress)2.99 (safe)5+

Piotroski F-Score

3 / 9 — Weak

Nine binary checks across profitability, leverage/liquidity, and operating efficiency. 7+ = financially strong; 4–6 = average; 0–3 = weak signals.

Profitability (1–4)

Leverage (5–7)

Efficiency (8–9)

Positive net income

Positive operating cash flow

Improving return on assets

Cash flow exceeds net income

Debt ratio reduced

Improving current ratio

No equity dilution

Improving gross margin

Improving asset turnover

Calculated from annual report data sourced via BSE/NSE filings. For precise figures refer to BSE/NSE filings.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹1,875 Cr

Net profit

₹322 Cr

Operating margin

—

Net margin

17.2%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹246.37 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹62.02 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹52 Cr

Equity

₹3,106 Cr

Debt / Equity

0.02×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

62.4%

FII

5.6%

-0.4 pp QoQ

DII

16.1%

+0.5 pp QoQ

Retail

15.9%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	53.2%	53.2%	53.1%	66.0%	62.6%	62.4%	62.4%	62.4%	62.4%	62.4%	62.4%	62.4%	-0.0 ppYoY
FII (Foreign)	14.5%	14.1%	12.4%	9.9%	11.9%	12.3%	11.5%	11.4%	9.8%	9.4%	5.9%	5.6%	-5.9 ppYoY
DII (Domestic)	5.2%	5.5%	7.2%	9.3%	12.3%	11.7%	12.0%	11.7%	13.5%	13.8%	15.6%	16.1%	+4.4 ppYoY
Retail	27.2%	27.3%	27.3%	14.7%	13.2%	13.6%	14.1%	14.4%	14.3%	14.3%	16.1%	15.9%	+1.5 ppYoY

Signals from the trend

📈

PromoterUp 9.3pp — insiders are adding to their stake

📉

FIINet sellers (8.9pp) — foreign institutional interest is declining

📈

DIINet buyers (+10.9pp) — domestic funds are accumulating

Mixed signals — promoter buying and DII buying on the positive side, but FII outflows adds uncertainty.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.